Real-World Feasibility, Toxicity, and Early Outcomes of Neoadjuvant Pembrolizumab-Based Systemic Therapy in Early Triple-Negative Breast Cancer: A Single-Centre Chinese Cohort from Hong Kong

Background

Neoadjuvant treatment for early-stage triple-negative breast cancer has been widely used, and the KEYNOTE-522 (KN522) regimen has become a standard of care for early-stage TNBC, with alternative treatment options including a dose-dense anthracycline/taxane-based regimen for patients without access to neoadjuvant immunotherapy. Nevertheless, real-world evidence in Chinese populations, especially high-risk cohorts such as older populations and those with substantial nodal burden, is limited regarding both efficacy and tolerability. This study describes the outcomes associated with neoadjuvant systemic therapy in a Hong Kong Chinese cohort.